User profiles for Alyson Haslam

Alyson Haslam

University of California San Francisco
Verified email at ucsf.edu
Cited by 2333

Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs

A Haslam, V Prasad - JAMA network open, 2019 - jamanetwork.com
Importance Immunotherapy checkpoint inhibitors have generated considerable interest
because of durable responses in a number of hitherto intractable tumor types. Objective To …

Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs

A Haslam, J Gill, V Prasad - JAMA network Open, 2020 - jamanetwork.com
Immune checkpoint inhibitor (ICI) drugs have gained popularity in oncology because of their
ability to boost a person’s immune response against cancer cells. 1 We recently estimated …

[HTML][HTML] A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology

A Haslam, SP Hey, J Gill, V Prasad - European Journal of Cancer, 2019 - Elsevier
Background Surrogates are frequently used in cancer medicine as the end-point of clinical
trials and as the basis of United States Food and Drug Administration approvals, but they do …

Anticancer drugs approved by the US food and drug administration from 2009 to 2020 according to their mechanism of action

T Olivier, A Haslam, V Prasad - JAMA network open, 2021 - jamanetwork.com
Importance Both novel and next-in-class cancer drugs have a role in oncology, but the relative
development of each is understudied. Objective To characterize the mechanisms of action …

A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals

D Herrera-Perez, A Haslam, T Crain, J Gill… - Elife, 2019 - elifesciences.org
10.7554/eLife.45183.001 The ability to identify medical reversals and other low-value
medical practices is an essential prerequisite for efforts to reduce spending on such practices. …

FDA acceptance of surrogate end points for cancer drug approval: 1992-2019

EY Chen, A Haslam, V Prasad - JAMA internal medicine, 2020 - jamanetwork.com
Methods| A retrospective review of cancer drugs approved from January 1992 through July
2019 on the basis of surrogate end points, either response rate or progression-free survival, …

Patient experience captured by quality-of-life measurement in oncology clinical trials

A Haslam, D Herrera-Perez, J Gill… - JAMA network open, 2020 - jamanetwork.com
Importance Quality of life (QoL) is an important consideration in cancer medicine, especially
because drugs are becoming more costly and may only result in modest gains in overall …

Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015-2020

A Haslam, MP Lythgoe, EG Akman… - JAMA network open, 2021 - jamanetwork.com
Importance Increasingly, cost-effectiveness analyses are being done to determine the value
of rapidly increasing oncology drugs; however, this assumes that these analyses are …

[HTML][HTML] FDA validation of surrogate endpoints in oncology: 2005–2022

A Walia, A Haslam, V Prasad - Journal of Cancer Policy, 2022 - Elsevier
Introduction The number of oncologic drugs approved by the US Food and Drug Administration
(FDA) on the basis of surrogate endpoints is rising. However, many surrogates have not …

Estimation of eligibility for and response to CAR-T therapy in the United States

A Haslam, TB Hoeg, V Prasad - Blood Advances, 2024 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell (CAR-T) therapies genetically modify a person’s
own T cells to bind to antigens expressed on cancer cells. 1, 2 CAR-T has generated sizable …